MET-dependent solid tumours — molecular diagnosis and targeted therapy | Nature Reviews Clinical Oncology
Clinical analysis by next-generation sequencing for NSCLC patients with MET amplification resistant to osimertinib - Lung Cancer
A first-in-human phase I study of SAR125844, a selective MET tyrosine kinase inhibitor, in patients with advanced solid tumours with MET amplification - European Journal of Cancer
Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752. - Abstract - Europe PMC
BRAF V600E mutation and MET amplification as resistance pathways of the second-generation anaplastic lymphoma kinase (ALK) inhibitor alectinib in lung cancer - Lung Cancer
MET/HGF pathway activation as a paradigm of resistance to targeted therapies - Ko - Annals of Translational Medicine
Resistance to epidermal growth factor receptor inhibitors in non-small cell lung cancer and strategies to overcome it | Australian Medical Student Journal
Liquid biopsy data to detect METex14 changes and MET amplification in patients with advanced lung cancer are presented in the AACR - Onco Americas
Read in JCO:... - American Society of Clinical Oncology | Facebook
Targeting the MET Pathway for Lung Cancer Treatments, Biomarkers
Genes - Mass General Cancer Center
Targeting MET in Lung Cancer: Will Expectations Finally Be MET? - ScienceDirect
Targeting MET in Cancer: Obstacles and Potentials | Insight Medical Publishing
Is there a place for crizotinib in c-MET alterations? A case of efficacy in ALK positive NSCLC patient with secondary c-MET amplification - Annals of Oncology
MET amplification results in heterogeneous responses to osimertinib in EGFR‐mutant lung cancer treated with erlotinib - Nishiyama - 2020 - Cancer Science - Wiley Online Library
The clinical efficacy of combinatorial therapy of EGFR-TKI and crizotinib in overcoming MET amplification-mediated resistance from prior EGFR-TKI therapy - Lung Cancer
Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy | Nature Reviews Cancer
What Is Met Amplification
Antonio Passaro on Twitter: "Great slides @ChristianRolfo on diagnostic challenges on MET amplification. #biomarker #lcsm #LungCancer… "
Capmatinib in MET Exon 14–Mutated or MET-Amplified Non–Small-Cell Lung Cancer | NEJM
Met signaling pathway and EGF receptor tyrosine kinase inhibitor... | Download Scientific Diagram
Targeting MET in Lung Cancer: Will Expectations Finally Be MET? - Journal of Thoracic Oncology
MET amplification causes EGFR-TKI resistance by activating... | Download Scientific Diagram
MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling | Science
Does c-Met remain a rational target for therapy in patients with EGFR TKI-resistant non-small cell lung cancer? - Cancer Treatment Reviews
Cancers | Free Full-Text | Targeting MET Amplification as a New Oncogenic Driver | HTML
C-Met - Wikipedia
